Celltrion Gets Phase IIb Green Light For Universal Influenza Antibody Drug
Executive Summary
Hot on the heels of its biosimilar deal with Teva, Celltrion is also making a progress in development of novel drugs, receiving the green light for Phase IIb trial in South Korea for CT-P27, its in-house universal therapeutic antibody product for influenza.
You may also be interested in...
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.